Summary
People with ADHD are dramatically overrepresented in prison populations. How dramatically depends on which meta-analysis you read, and the field is actively debating the numbers. But even the most conservative estimate puts the prevalence at several times the general population rate, and the most commonly cited figures suggest that roughly one in four prisoners meets diagnostic criteria for ADHD, against a background rate of 2.5 to 4% in the adult general population.
The numbers matter, but the pattern behind them matters more. ADHD in prison is not an accident of statistics. It is the endpoint of a pathway that starts with an undiagnosed child in a classroom that cannot accommodate their neurology, passes through school exclusion, social marginalisation, substance use, and impulsive decision-making, and arrives at a criminal justice system that has no routine mechanism for identifying the condition, let alone treating it. At every stage of this pathway, the system could intervene. At almost every stage, it does not.
This page traces that pathway, examines the evidence, and asks the question the numbers force: if ADHD is treatable, and if treatment reduces offending, then what does it mean that the people who most need diagnosis are the people least likely to receive it?
The prevalence debate
The headline figure, frequently cited and frequently contested, comes from a series of meta-analyses spanning the last decade. The numbers have not converged.
Young et al.’s early meta-analysis (2015, building on Young and Thome 2011) found a fivefold increase in youth prison populations (30.1%) and a tenfold increase in adult prison populations (26.2%) compared with general population prevalence. Baggio et al. (2018), in a systematic review and meta-analysis published in Frontiers in Psychiatry, pooled diagnostic interview data from 83 samples and estimated prevalence at 26.7% across all people living in detention.
Fazel and Favril (2024) challenged these estimates in an updated meta-analysis published in Criminal Behaviour and Mental Health. Using stricter inclusion criteria, they limited their analysis to 11 studies reporting robust diagnostic data on 3,919 unselected adult prisoners and arrived at a prevalence of 8.3%, or approximately one in twelve. They argued that earlier estimates were inflated by selected samples, self-report screening tools with high false-positive rates, and the inclusion of studies from specialised prison psychiatric units.
Baggio and Efthimiou (2024) published a direct response in the same journal, reanalysing Fazel and Favril’s data and arriving at a pooled estimate of 22.2%. They argued that Fazel and Favril’s exclusion criteria were too restrictive and their analytical methods suboptimal. Fazel and Favril (2024b) responded in turn, defending their methodological choices.
The disagreement is partly technical (which studies to include, how to handle heterogeneity) and partly conceptual (what counts as a valid diagnostic assessment in a prison context). Screening tools identify more people than diagnostic interviews. Self-report measures capture more than clinician-administered ones. Whether the higher or lower estimates are “correct” depends in part on what question you are asking. If the question is how many prisoners would receive a clinical diagnosis of ADHD from a specialist, the lower estimate may be closer. If the question is how many prisoners have clinically significant ADHD symptoms that affect their functioning and their risk of reoffending, the higher estimates are more relevant.
What is not in dispute is that the prevalence, however you measure it, is substantially higher than in the general population. The debate is about whether the overrepresentation is fivefold or tenfold. It is not about whether it exists.
The pathway
The overrepresentation does not appear from nowhere. The research describes a developmental trajectory, not a single cause, in which ADHD interacts with environmental failures at multiple stages to produce criminal justice involvement.
Childhood: the missed diagnosis
ADHD is one of the most heritable neurodevelopmental conditions, present from early childhood. In a well-resourced environment with informed parents, teachers, and clinicians, it is identifiable and treatable. In practice, diagnosis rates vary enormously by socioeconomic status, race, and gender. Black children in the US are diagnosed with ADHD at lower rates than white children despite similar or higher symptom prevalence, and when diagnosed they are less likely to receive medication (a disparity documented repeatedly, most recently in a 2025 analysis in Children and Youth Services Review examining untreated ADHD as a contributor to the school-to-prison pipeline and related racial disparities). Girls with ADHD, whose symptoms more often present as inattention rather than hyperactivity, are diagnosed later and less frequently than boys.
The children who are most likely to end up in the criminal justice system are the children who are least likely to have received an accurate diagnosis and appropriate support. This is not a coincidence. It is a selection effect: the same social disadvantages that reduce access to diagnosis also increase exposure to the risk factors for offending.
School: exclusion as inflection point
In the UK, 39% of children with ADHD have experienced fixed-term exclusion from school, and 11% have been permanently excluded. Children with special educational needs represent approximately half of all permanent exclusions in England despite making up only 17% of the school population. A 2024 study from the University of Exeter, funded by the ESRC and published in Forensic Science International: Mind and Law, found that neurodisability (including ADHD) in children was directly linked to vulnerability to the “school-to-prison pipeline,” with school exclusion acting as a measurable inflection point: the more times a child had been excluded, the younger they were when first convicted.
The mechanism is not mysterious. A child with undiagnosed ADHD in a classroom with thirty other children is a child who cannot sit still, cannot sustain attention on material that does not interest them, blurts out answers, fidgets, disrupts. Without a diagnosis, these behaviours are interpreted as defiance. The response is disciplinary: detention, suspension, exclusion. Each exclusion removes the child from the educational environment, disrupts their social relationships, increases their contact with other excluded young people (who share similar risk profiles), and reduces the likelihood that they will complete their education. The child has not chosen this pathway. The system has failed to recognise their neurology and has responded to the visible behaviour rather than its cause.
Substance use: self-medication and risk
ADHD is strongly associated with substance use disorders. The association is bidirectional: ADHD increases the risk of substance use, and substance use complicates the identification and treatment of ADHD. But the self-medication hypothesis, supported by both clinical evidence and the testimony of people with ADHD themselves, adds a specific mechanism. Dopaminergic stimulants (nicotine, cocaine, amphetamines) temporarily address the neurochemical profile that underlies ADHD symptoms. People with undiagnosed, untreated ADHD who discover that certain substances make their minds quieter, more focused, more manageable are not making irrational choices. They are solving a problem that nobody else has helped them solve, using the tools available to them.
Incarcerated people with ADHD have a significantly higher risk of lifetime substance use disorder (odds ratio 2.17) and current substance use disorder (odds ratio 2.08) compared with incarcerated people without ADHD. Nearly 60% of individuals arrested for drug offences in the Brown et al. (2025) London Metropolitan Police study had an existing diagnosis or a positive screening result for ADHD.
The overlap between ADHD, substance use, and offending creates a diagnostic tangle. In prison, ADHD symptoms may be attributed to substance withdrawal or to antisocial personality disorder. The underlying condition disappears behind its consequences, and the person is treated (or not treated) for everything except the thing driving the rest of it.
Impulsivity and the moment of offending
ADHD impulsivity is not recklessness. It is a difference in the speed at which the brain evaluates consequences before acting. The gap between impulse and action, the pause in which a neurotypical person might think “this is a bad idea,” is shortened. This does not make criminal behaviour inevitable. Most people with ADHD never commit a crime. But it means that in the specific circumstances that lead to offending (interpersonal conflict, intoxication, provocation, perceived threat), the person with ADHD has less neurological buffer between the impulse and the act.
This has legal as well as clinical implications. ADHD impulsivity is a mitigating factor in sentencing in some jurisdictions, though its recognition is inconsistent. The question of moral and legal responsibility for impulsive acts committed by people with a neurological condition that specifically impairs impulse control is an ethical question the justice system has not resolved (see The ethics of intervention).
Half of London’s arrestees
In 2025, Brown et al. published “Neurodiversity in Custody” in Criminal Behaviour and Mental Health, reporting the results of screening 216 individuals arrested and detained at six London Metropolitan Police custody centres over an eight-week period. The findings were striking: 50% of arrestees without an existing ADHD diagnosis screened positive for ADHD, warranting further assessment. An additional 4.2% already had a diagnosis. Only 5.4% screened positive for possible undiagnosed autism.
The study used the Adult ADHD Self-Report Scale (ASRS) and the 10-item Autism-Spectrum Quotient (AQ-10). These are screening instruments, not diagnostic tools: they identify people who should be assessed further, not people who definitively have the condition. The 50% figure does not mean half of London’s arrestees have ADHD. It means that half of them show enough symptoms to warrant a proper assessment, and that almost none of them have ever received one.
Cambridge University’s press release used the headline “Half of people arrested in London may have undiagnosed ADHD.” That “may” is doing a lot of work, but the underlying point stands: the criminal justice system is processing vast numbers of people with likely undiagnosed neurodevelopmental conditions, and it has no systematic process for finding out.
The treatment gap
The evidence that treating ADHD reduces offending is unusually strong for a criminal justice intervention.
Lichtenstein et al. (2012), in a landmark study published in the New England Journal of Medicine, used Swedish national registry data covering 25,656 adults with ADHD diagnoses over four years. Using a within-individual design (comparing the same person’s offending rate during medicated and unmedicated periods), they found that ADHD medication reduced criminality by 32% in men and 41% in women. The effect applied equally to petty crime and serious or violent offences.
The implication is direct: a treatable condition is contributing to criminal behaviour, and treating it reduces that behaviour by roughly a third. Lichtenstein himself noted that 30 to 40% of long-serving prisoners have ADHD, and that a 30% reduction in their reoffending rate would have measurable effects on crime at a population level.
And yet. Young et al.’s (2018) expert consensus statement, published in BMC Psychiatry, documented the barriers that prevent this evidence from translating into practice. In the criminal justice system, ADHD remains both underdiagnosed and undertreated. The specific barriers include: lack of staff awareness of ADHD symptoms, absence of trained mental health professionals in prisons, no standardised screening tool used across the system, restrictive prescribing policies for stimulant medication in custodial settings (driven by concerns about diversion and substance misuse), and inadequate continuity of care between prison and community on release.
The prescribing question is particularly revealing. Stimulant medication is the most effective treatment for ADHD. It is also a controlled substance. In a prison environment where substance misuse is endemic, prescribing stimulants raises legitimate concerns about diversion. But the response in most jurisdictions has been to restrict prescribing rather than to develop safe prescribing protocols, effectively denying treatment because the environment is difficult. The Australian ADHD clinical practice guideline (AADPA) notes that people in the correctional system represent a specific subgroup requiring adapted approaches, but the gap between guideline and implementation remains wide.
Women, invisibility, and compounding disadvantage
Women with ADHD in the criminal justice system face a specific pattern of diagnostic invisibility. Their ADHD is less likely to have been identified in childhood (the inattentive presentation is more common and less disruptive, so it attracts less clinical attention). Their symptoms in adulthood are more likely to be attributed to co-occurring conditions: anxiety, depression, PTSD, borderline personality disorder, all of which occur at elevated rates in incarcerated women and all of which can mask underlying ADHD.
The result is that women in prison with ADHD are among the most diagnostically hidden people in the system. Their impulsivity may be attributed to personality disorder. Their substance use may be treated as a primary condition rather than as self-medication for an undiagnosed neurodevelopmental one. Their difficulties with routine, organisation, and emotional regulation, core ADHD features, may be interpreted as non-compliance. Lichtenstein’s finding that medication reduces offending more in women (41%) than in men (32%) suggests that the treatment gap for women with ADHD may be an even larger missed opportunity than for men.
Race, diagnosis, and the pipeline
The school-to-prison pipeline is not colour-blind. In the US, Black students are suspended and expelled at three times the rate of white students. Black children are diagnosed with ADHD at lower rates than white children with comparable symptoms, and when diagnosed, they are less likely to receive treatment. The 2025 analysis in Children and Youth Services Review connected these facts explicitly: untreated ADHD is a root cause in the developmental trajectory that leads to offending, and racial disparities in ADHD diagnosis and treatment contribute directly to racial disparities in the criminal justice system.
The UK data tells a parallel story. Children from disadvantaged backgrounds, including ethnic minority children who face systemic barriers to diagnosis, are overrepresented in school exclusion statistics and in the youth justice system. The Exeter study’s finding that neurodisability is linked to the school-to-prison pipeline carries an implicit equity dimension: if the children being excluded are disproportionately from marginalised communities, and if their neurodisability is disproportionately undiagnosed, then the pipeline is not just a failure of healthcare. It is a mechanism of structural inequality (see Intersectional neurodiversity).
What this means
The evidence base here is not ambiguous. ADHD is overrepresented in prison. Undiagnosed ADHD contributes to the pathway that leads to prison. Treatment reduces offending. And the system does not screen for, diagnose, or treat the condition.
This is not a medical curiosity. It is a policy failure with measurable consequences: in reoffending rates, in prison populations, in the lives of people whose neurodevelopmental condition was never identified and whose behaviour was punished rather than understood. The school-to-prison pipeline is, in part, an ADHD-to-prison pipeline, and every stage of it represents a point where intervention was possible and did not happen.
The neurodiversity framing matters here. If ADHD is understood as a neurological difference rather than a character flaw, then the failure to identify and support it before it leads to offending is not just a clinical oversight. It is an epistemic and ethical failure: the system does not see the person’s neurology, interprets their behaviour through a lens of defiance and deviance, and responds with punishment rather than support. The child who could not sit still becomes the teenager who is excluded, becomes the adult who self-medicates, becomes the prisoner who is never diagnosed (see Epistemic justice and neurodivergence).
The comparison with physical health is instructive. If a treatable physical condition were found in a quarter of prisoners, and if treating it reduced reoffending by a third, the failure to screen and treat would be a scandal. For ADHD, the evidence is there and the scandal is quiet.
Open questions
How should the criminal justice system handle the tension between stimulant prescribing and the risk of diversion in custodial settings? Safe prescribing protocols exist but are not widely implemented. The alternative, withholding effective treatment because the environment is difficult, is ethically hard to defend.
What would routine ADHD screening at arrest or intake look like in practice? The Brown et al. (2025) study demonstrated that screening is feasible in custody settings. Whether it can be scaled, and what clinical pathways it would feed into, remains to be worked out.
How should courts account for ADHD in sentencing? The condition directly affects impulse control, decision-making, and the capacity to foresee consequences. Legal systems are beginning to recognise this, but the recognition is inconsistent and often depends on the defendant’s ability to afford expert testimony.
Key sources
- Baggio, S., Fructuoso, A., Guimaraes, M., Fois, E., Golay, D., Heller, P., Perroud, N., Aubry, C., Young, S., Delessert, D., Getaz, L., Tran, N.T. and Wolff, H. (2018). Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: a systematic review and meta-analysis. Frontiers in Psychiatry, 9, 331. https://doi.org/10.3389/fpsyt.2018.00331
- Baggio, S. and Efthimiou, O. (2024). Meta-analysis of the prevalence of attention-deficit hyperactivity disorder in prison: a comment on Fazel and Favril (2024) and reanalysis of the data. Criminal Behaviour and Mental Health, 34(4), 304-310. https://doi.org/10.1002/cbm.2347
- Brown, N. et al. (2025). Neurodiversity in Custody: screening results for ADHD and autistic traits in individuals arrested by the London Metropolitan Police. Criminal Behaviour and Mental Health. https://doi.org/10.1002/cbm.70018
- Fazel, S. and Favril, L. (2024). Prevalence of attention-deficit hyperactivity disorder in adult prisoners: an updated meta-analysis. Criminal Behaviour and Mental Health, 34(3), 190-199. https://doi.org/10.1002/cbm.2337
- Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjolander, A., Serlachius, E., Fazel, S., Langstrom, N. and Larsson, H. (2012). Medication for Attention Deficit-Hyperactivity Disorder and Criminality. New England Journal of Medicine, 367(21), 2006-2014. https://doi.org/10.1056/NEJMoa1203241
- Young, S., Moss, D., Sedgwick, O., Fridman, M. and Hodgkins, P. (2015). A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychological Medicine, 45(2), 247-258. https://doi.org/10.1017/S0033291714000762
- Young, S., Gonzalez, R.A., Fridman, M., Hodgkins, P., Kim, K., Oesterle, T.S. and Ramos-Quiroga, J.A. (2018). Identification and treatment of offenders with attention-deficit/hyperactivity disorder in the prison population: a practical approach based upon expert consensus. BMC Psychiatry, 18, 281. https://doi.org/10.1186/s12888-018-1858-9